Comparative Pharmacology
Head-to-head clinical analysis: NEXTSTELLIS versus NIKKI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEXTSTELLIS versus NIKKI.
NEXTSTELLIS vs NIKKI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: estrogen (estetrol) and progestin (drospirenone) suppress gonadotropin release, inhibiting ovulation; increase cervical mucus viscosity, impeding sperm penetration; alter endometrial lining, reducing implantation likelihood.
NIKKI is a combination oral contraceptive containing ethinyl estradiol and drospirenone. Drospirenone is a progestin with antimineralocorticoid and antiandrogenic activity. It suppresses gonadotropin release, thereby inhibiting ovulation.
One tablet orally once daily, each tablet containing drospirenone 3 mg and estetrol 14.2 mg, taken continuously without a break.
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Drospirenone: 30 hours; ethinyl estradiol: 12 hours. The long half-life allows once-daily dosing and stable serum concentrations.
Terminal elimination half-life: 12-15 hours; clinical context: allows once-daily dosing; steady-state reached in ~3 days
Urine (60%) and feces (35%); drospirenone and metabolites, with enterohepatic recirculation.
Renal: 50% (20% unchanged, 30% as metabolites); Fecal: 40%; Biliary: 10%
Category C
Category C
Contraceptive
Contraceptive